COMP <GO>
FATE vs LXEO // EV/EBITDA & P/E VALUATION
Fate Therapeutics Inc. (NASDAQ) VS. Lexeo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: FATE 2
— LXEO 1
■ METRIC PARITY
LAST: $2.17 (0.00%) • MKT CAP: $260.0M
valuation
—
LAST: $3.06 (-2.24%) • MKT CAP: $251.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FATE VS. LXEO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FATE | LXEO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -51.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | FATE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 48.3 | -3.06 | LXEO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $260.0M | $251.1M | $8.9M | FATE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FATE REV | LXEO REV | FATE GROSS % | LXEO GROSS % | FATE FCF | LXEO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.6M | $0 | — | — | -$112.0M | -$99.0M |
| FY 2024 | $13.6M | $0 | — | — | -$123.6M | -$81.6M |
| FY 2023 | $63.5M | $0 | — | — | -$132.3M | -$59.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FATE // BETA —
LXEO // BETA —